Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates

Digestive Diseases and Sciences

Volumn 48, Issue 11, 2003, Pages 2173-2181

  Loria, Paola ^a,d   Lonardo, Amedeo ^b   Leonardi, Francesca ^a   Fontana, Cristina ^a   Carulli, Lucia ^a   Verrone, Anna Maria ^a   Borsatti, Andrea ^a   Bertolotti, Marco ^a   Cassani, Fabio ^c   Bagni, Alberto ^a   Muratori, Paolo ^c   Ganazzi, Dorval ^a   Bianchi, Francesco B ^c   Carulli, Nicola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Ospedale di Modena   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Autoimmune hepatitis; Autoimmunity; Liver biopsy; NASH; NOSA

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CERULOPLASMIN; COPPER; IMMUNOGLOBULIN; MITOCHONDRION ANTIBODY; SMOOTH MUSCLE ANTIBODY; STEROID;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; AUTOIMMUNE HEPATITIS; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOFLUORESCENCE; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; AUTOANTIBODIES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MITOCHONDRIA, LIVER; MUSCLE, SMOOTH; SEROEPIDEMIOLOGIC STUDIES;

EID: 9144258000     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DDAS.0000004522.36120.08     Document Type: Article

References (50)

1. Czaja AJ: Autoantibodies. Baillieres Clin Gastroenterol 9:723-744, 1995
2. Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Blanchi FB, Tiribelli C, Prevalence of non-organ specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dyonisos cohort. Gut 45:435-141, 1999
3. Czaja AJ, Carpenter HA, Santrach PJ, Moore B: Genetic predisposition for immunologic features in chronic liver diseases other than autoimmune hepatitis, J Hepatol 24:52-59, 1996
4. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002
5. Day CP: Non-alcoholic steatohepatits (NASH): where are we now and where we going? Gut 50:585-588, 2002
6. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657, 2002
7. Lonardo A, Loria P, Carulli N: Insulin resistance in non-alcoholic fatty liver disease. In Steatohepatitis (NASH and ASH). U Leuschner, O James, H Dancygier (eds). Dordrecht, Kluwer Academic Publishers, 2001, pp. 104-113
8. Marchesini G, Forlani G: NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35:497-499, 2002
9. Festa A, D' Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 102:42-47, 2000
10. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 23:1835-1839, 2000
11. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C: Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 25:538-540, 1997
12. Tumiel M, Whitcomb BJ, Krawitt EL: Circulating antinuclear antibodies in patients with nonalcoholic steatohepatitis. Hepatology 20:409A, 1249, 1994; (abstract)
13. Caldwell SH, Oelsner DH, Jezzoni JC, Hesenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664-669, 1999
14. Bacon BR, Farawash MJ, Janney CG, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103-1109, 1994
15. Neuschwander-Tetri BA, Caldwell SH: Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:1202-1219, 2003
16. Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone AM, Bagni A, Bertolotti M, Ganazzi D, Carulli N: Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis 34:204-211, 2002
17. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 344:495-500, 2001
18. Johnson PJ, McFarlane IG: Meeting report: International Autoimmune Hepatitis Group. Hepatology 18:998-1005, 1993
19. Cassani F, Bianchi FB, Lenzi M, Volta U, Pisi E: Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J Clin Pathol 38:801-805, 1985
20. Cassani F, Fusconi M, Bianchi FB, Selleri L, Baffoni L, Lenzi M, Pisi E: Precipitating antibodies to rabbit thymus extractable antigens in chronic liver disease: relationship with antiactin antibodies. Clin Exp Immunol 68:588-595, 1987
21. Fusconi M, Baum H, Caselli A, Cassani F, Ballardini G, Lenzi M, Volta U, Zauli D, Bianchi FB: Demonstration of peptide-specific and cross-reactive epitopes in proteins reacting with antimitochondrial antibodies of primary biliary cirrhosis. J Hepatol 15:162-169, 1992
22. Brunt E, Janney C, Di Bisceglie A, Neuschwander-Tetri B, Bacon B: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474, 1999
23. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WGE, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston ALWF, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RNM, Maddrey WC, Manns MP, McFarlane IG, Meyerzum Büschenfelde K-H, Miell-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M: International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929-938, 1999
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
25. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative Insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402-2410, 2000
26. Abbasi F, Reaven GM: Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 51:235-237, 2002
27. Dixon JB, Bhatal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001
28. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, Fargion S: Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122:274-280, 2002
29. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart study. Diabetes Care 20:1087-1092, 1997
30. Laroussi N, Mosnier JF, Morel Y, Deugnier Y, Dumas O, Audigier JC: Non alcoholic steatohepatitis: a multifactorial, frequent, paucysymptomatic liver disease with a fibrotic outcome. Gastroenterol Clin Biol 26:475-479, 2002
31. De Jorge FB: Correlation between copper and transaminases in the blood serum in infectious hepatitis, during convalescence. Clin Chim Acta 20:111-112, 1968
32. Marniemi J, Jarvisalo J, Toikka T, Raiha I, Ahotupa M, Sourander L: Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population. Int J Epidemiol 27:799-807, 1998
33. Niskanen J, Marniemi J, Piironen O, Maatela J, Maki J, Vuori I, Seppanen A, Kallio V, Aromaa A: Trace element levels in serum and urine of subjects died of coronary heart disease. Acta Pharmacol Toxicol 59(suppl VII):340-343, 1986
34. Reunanen A, Knekt P, Marniemi J, Maki J, Maatela J, Aromaa A: Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr 50:431-437, 1996
35. Cousins RJ: Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 65:238-309, 1985
36. Natesha RK, Natesha R, Victory D, Barnwell SP, Hoover EL: A prognostic role for ceruloplasmin in the diagnosis of indolent and recurrent inflammation. J Natl Med Assoc 84:781-784, 1992
37. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y: Regular physical activity and coronary risk factors in Japanese men. Circulation 97:661-665, 1998
38. Czaja AJ: Autoantibodies in liver disease. Gastroenterology 120:239-249, 2001
39. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC: Non-alcoholic fatty liver disease, another feature of the metabolic syndrome? Clin Nutr 18:253-258, 1999
40. Forouhi NG, Sattar N, McKeigue PM: Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes 25:1327-1331, 2001
41. Hay JE, Czaja AJ, Rakela J, Ludwig J: The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 9:193-197, 1989
42. Knobler H, Schattner A, Zhomicki T, Malnick SD, Keter D, Sokolovskaya N, Lurie Y, Bass: Fatty liver. An additional and treatable feature of the insulin resistance syndrome. Q J Med 92:73-79, 1999
43. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in nonalcoholic steatohepatitis. Lancet 358:893-894, 2001
44. Facchini FS, Hua NW, Stoohs RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122:931-939, 2002
45. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96:2448-2455, 2001
46. Tazawa Y, Noguchi H, Nishinomiya F, Takada G: Effect of weight changes on serum transaminase activities in obese children. Acta Paediatr Jpn 39:210-214, 1997.
47. Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, Budillon G, Cimino L, Di Carlo A, Di Marino MP, Morisco F, Picciotto F, Terracciano L, Vecchione R, Verde V, Del Vecchio Blanco C: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 35:568-574, 2001
48. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23:1464-1467, 1996
49. Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ: Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 35:409-413, 2002
50. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I: Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13:490-495, 1998